Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Clinical Trials

Clinical Management of Antiplatelet Drug Resistance in Patients With Drug Eluting Coronary Stents

Phase 4

Withdrawn

Conditions: Coronary Artery Disease

Interventions: Drug: Plavix (Clopidogrel)

First Posted Date: 2008-01-10

Last Posted Date: 2015-11-30

Lead Sponsor: Creighton University

Registration Number: NCT00589862

Locations: 🇺🇸
Creighton University Medical Center, Omaha, Nebraska, United States

Safety of High-dose Tirofiban During Coronary Angioplasty

Phase 4

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: tirofiban
Drug: Clopidogrel

First Posted Date: 2007-12-04

Last Posted Date: 2011-02-02

Lead Sponsor: S. Anna Hospital

Target Recruit Count: 2000

Registration Number: NCT00566891

Locations: 🇮🇹
S Anna Hospital, Catanzaro, Italy

Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)

Phase 3

Terminated

Conditions: Acute Coronary Syndrome
Myocardial Infarction
Coronary Artery Disease
Percutaneous Coronary Intervention

Interventions: Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin
Drug: Plavix (clopidogrel 75 mg) and aspirin

First Posted Date: 2007-11-14

Last Posted Date: 2009-01-28

Lead Sponsor: Cogentus Pharmaceuticals

Target Recruit Count: 5000

Registration Number: NCT00557921

Locations: 🇺🇸
Piedmont Hospital, Atlanta, Georgia, United States
🇺🇸
Primary Care Specialists, LLC/ ECAST CT, Atlanta, Georgia, United States
🇺🇸
Midwest Cardiology Research Foundation, Columbus, Ohio, United States

and more 469 locations

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

Phase 2

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Clopidogrel (over encapsulated) capsule
Drug: Ticagrelor Tablets
Drug: Aspirin Tablets

First Posted Date: 2007-09-12

Last Posted Date: 2012-01-13

Lead Sponsor: AstraZeneca

Target Recruit Count: 123

Registration Number: NCT00528411

Locations: 🇬🇧
Research Site, Sheffield, United Kingdom

Platelet Function Assessment for Atherothrombotic Patients

Phase 4

Conditions: Coronary Artery Disease

Interventions: Drug: Clopidogrel

First Posted Date: 2007-08-08

Last Posted Date: 2011-01-24

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 150

Registration Number: NCT00513149

Locations: 🇨🇳
Division of Cardiology, Department of Internal Medicine and Department of Medical Imaging, National Taiwan University Hospital, Taipei, Taiwan